Silo Pharma, Inc.
SILO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | 0.05 | 0.03 | -0.01 |
| FCF Yield | -14.84% | -32.49% | -31.26% | -22.99% |
| EV / EBITDA | -2.19 | 0.31 | -2.06 | -0.05 |
| Quality | ||||
| ROIC | 235.94% | -22.29% | -23.21% | -31.50% |
| Gross Margin | -14.77% | 91.91% | 91.90% | 91.90% |
| Cash Conversion Ratio | 0.86 | -1.25 | 1.59 | 0.53 |
| Growth | ||||
| Revenue 3-Year CAGR | -0.00% | -0.00% | -0.00% | -0.00% |
| Free Cash Flow Growth | 25.66% | 21.64% | -78.79% | 31.87% |
| Safety | ||||
| Net Debt / EBITDA | 3.40 | 3.61 | 3.06 | 2.18 |
| Interest Coverage | 1,299.62 | -757.62 | -529.58 | -6,618.07 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -60,316.35 | -68,621.98 | -97,637.36 |